| (210) | Number of the EPO application | 20183402 |
| (220) | Filing date of the EPO application | 2018.09.13 |
| (80) | EPO patent specification publication (B) | EPB nr. 18/2021, 2021.05.05 |
| (110) | EPO patent number | 3736270 |
| (11) | Number of the document | MD 3736270 T2 |
| (21) | Number of the application | e 2020 1159 |
| (71) | Name(s) of applicant(s), code of the country | AbbVie Overseas S.à r.l., LU;
Galapagos N.V., BE; |
| (72) | Name(s) of inventor(s), code of the country | ALTENBACH Robert J, US;
BOGDAN Andrew, US;
COUTY Sylvain, FR;
DESROY Nicolas, FR;
GFESSER Gregory A., US;
HOUSSEMAN Christopher Gaëtan, FR;
KYM Philip R., US;
LIU Bo, US;
MAI Thi Thu Trang, FR;
MALAGU Karine Fabienne, GB;
MERAYO MERAYO Nuria, FR;
PICOLET Olivier Laurent, FR;
PIZZONERO Mathieu Rafaël, FR;
SEARLE Xenia B., US;
VAN DER PLAS Steven Emiel, BE;
WANG Xueqing, US;
YEUNG Ming C., US; |
| (73) | Name(s) of owner(s), code of the country | ABBVIE Overseas S.à r.l., LU;
Galapagos N.V., BE; |
| (54) | Title of the invention | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 401/12 (2006.01.01); C07D 213/71 (2006.01.01); C07D 215/36 (2006.01.01); C07D 231/56 (2006.01.01); C07D 235/28 (2006.01.01); C07D 471/04 (2006.01.01); C07D 213/64 (2006.01.01); C07C 311/45 (2006.01.01); A61P 11/00 (2006.01.01); A61K 31/4709 (2006.01.01) |
| (19) | Country | LU |
| (41) | Date of publication of the application | 2020.12.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2021.11.30 |
| (30) | Priority | 201762558430 P, 2017.09.14, US; 201762608846 P, 2017.12.21, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |